Literature DB >> 1314854

High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia.

W Digel1, F Porzsolt, M Schmid, F Herrmann, W Lesslauer, M Brockhaus.   

Abstract

The presence of soluble tumor necrosis factor (TNF) binding proteins (BP) was investigated in the sera of healthy volunteer blood donors and cancer patients. Two distinct types of TNFBP, types A and B, which are immunologically related to the cellular 75-kD TNF receptor (TNFR) and the cellular 55-kD TNFR, respectively, were assessed by immunoassays using nonblocking anti-receptor antibodies and 125I-recombinant human TNF alpha. As compared to the titers observed in 25 healthy controls, TNFBP types A and B titers were found to be elevated in almost all sera obtained from patients with underlying malignant disease. The highest amounts of TNFBP were seen in the sera of patients with B cell malignancies including hairy cell leukemia (HCL) and type B chronic lymphocytic leukemia. Treatment of HCL patients with recombinant human interferon-alpha was associated with decrease of circulating TNFBP.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314854      PMCID: PMC443049          DOI: 10.1172/JCI115769

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

Review 2.  Cachectin/tumour necrosis factor.

Authors:  K J Tracey; H Vlassara; A Cerami
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

3.  Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease.

Authors:  R Foa; M Massaia; S Cardona; A G Tos; A Bianchi; C Attisano; A Guarini; P F di Celle; M T Fierro
Journal:  Blood       Date:  1990-07-15       Impact factor: 22.113

4.  Antiviral effects of recombinant tumour necrosis factor in vitro.

Authors:  J Mestan; W Digel; S Mittnacht; H Hillen; D Blohm; A Möller; H Jacobsen; H Kirchner
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

5.  Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia.

Authors:  W Digel; M Stefanic; W Schöniger; C Buck; A Raghavachar; N Frickhofen; H Heimpel; F Porzsolt
Journal:  Blood       Date:  1989-04       Impact factor: 22.113

6.  Molecular cloning and expression of a receptor for human tumor necrosis factor.

Authors:  T J Schall; M Lewis; K J Koller; A Lee; G C Rice; G H Wong; T Gatanaga; G A Granger; R Lentz; H Raab
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

7.  Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.

Authors:  M Brockhaus; H J Schoenfeld; E J Schlaeger; W Hunziker; W Lesslauer; H Loetscher
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

8.  Clinical staging system for hairy-cell leukemia.

Authors:  J Jansen; J Hermans
Journal:  Blood       Date:  1982-09       Impact factor: 22.113

9.  Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies.

Authors:  F T Cordingley; A Bianchi; A V Hoffbrand; J E Reittie; H E Heslop; A Vyakarnam; M Turner; A Meager; M K Brenner
Journal:  Lancet       Date:  1988-04-30       Impact factor: 79.321

10.  Shedding of tumor necrosis factor receptors by activated human neutrophils.

Authors:  F Porteu; C Nathan
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

View more
  15 in total

Review 1.  TNF ligands and receptors--a matter of life and death.

Authors:  David J MacEwan
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody.

Authors:  J Jansen; T van der Poll; M Levi; H ten Cate; H Gallati; J W ten Cate; S J van Deventer
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

3.  Kinetics of serum soluble tumour necrosis factor receptor (TNF-R) type-I and type-II after a single interferon-alpha (IFN-alpha) injection in chronic hepatitis C.

Authors:  C Fabris; M Del Forno; E Falleti; P Toniutto; M Pirisi
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

4.  Increased release of the tumour necrosis factor receptor p75 by immortalized human keratinocytes results from an activated shedding mechanism and is not related to augmented steady-state levels of p75 mRNA.

Authors:  P Neuner; M Pourmojib; G Klosner; F Trautinger; R Knobler
Journal:  Arch Dermatol Res       Date:  1996-10       Impact factor: 3.017

5.  Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I.

Authors:  C L Selinsky; K L Boroughs; W A Halsey; M D Howell
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

6.  Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.

Authors:  R Landmann; U Keilholz; C Scheibenbogen; M Brockhaus; H Gallati; H Denz; M Bargetzi; C Ludwig
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

7.  The 55-kD tumor necrosis factor receptor on human keratinocytes is regulated by tumor necrosis factor-alpha and by ultraviolet B radiation.

Authors:  U Trefzer; M Brockhaus; H Lötscher; F Parlow; A Budnik; M Grewe; H Christoph; A Kapp; E Schöpf; T A Luger
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia.

Authors:  G A Spinas; U Keller; M Brockhaus
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

9.  Interleukin-4 (IL-4) induces down-modulation and shedding of the p55 tumour necrosis factor receptor and inhibits TNF alpha's effect on rheumatoid synovial fibroblasts.

Authors:  D J Taylor
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

10.  The elevation of plasma soluble tumor necrosis factor receptor levels by TNF induction therapy for patients with malignancy.

Authors:  Y Abe; K Kimura; A Horiuchi; Y Watanabe; S Kimura
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.